<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026464</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201901829 -A</org_study_id>
    <nct_id>NCT04026464</nct_id>
  </id_info>
  <brief_title>Addition of Acetaminophen in Standard PDA Management</brief_title>
  <official_title>Monotherapy (Ibuprofen) vs. Combination Therapy (Ibuprofen and Acetaminophen) in the Management of Patent Ductus Arteriosus in Premature Infants: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patent ductus arteriosus is a common morbidity in preterm infants and management of PDA&#xD;
      varies among neonatologist. The investigators are conducting a randomized controlled trial to&#xD;
      determine the rates of initial patent ductus arteriosus (PDA) closure after completion of a&#xD;
      first treatment course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to obtain funding to support this project&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Actual">May 12, 2021</completion_date>
  <primary_completion_date type="Actual">May 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of infants with PDA closure.</measure>
    <time_frame>During hospitalization, up to 10 days</time_frame>
    <description>Percentage of patients who demonstrated PDA closure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Ibuprofen+Acetaminophen Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Ibuprofen</intervention_name>
    <description>The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.</description>
    <arm_group_label>Ibuprofen Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Ibuprofen + Oral Acetaminophen</intervention_name>
    <description>The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses.</description>
    <arm_group_label>Ibuprofen+Acetaminophen Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants 23 0/7 to 27 6/7 weeks' gestational age and birth weight &lt; 1000 grams&#xD;
&#xD;
          -  Hemodynamically significant PDA as defined by any of the following:&#xD;
&#xD;
               1. Increased ventilator or oxygen support attributed by the clinician to be due to&#xD;
                  increased left-right shunting through the PDA&#xD;
&#xD;
               2. Hypotension and/or widening pulse pressure requiring continuous dopamine infusion&#xD;
                  (hypotension is defined as mean arterial pressure (MAP) at least 2-3 mmHg below&#xD;
                  the infants' post menstrual age)&#xD;
&#xD;
               3. Signs of congestive heart failure (e.g increased pulmonary congestion on chest&#xD;
                  radiograph or hepatomegaly on physical examination)&#xD;
&#xD;
          -  Echocardiographic criteria:&#xD;
&#xD;
               1. Ratio of the smallest ductal diameter to the ostium of the left pulmonary artery&#xD;
                  &gt; 0.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No enteral feedings&#xD;
&#xD;
          -  PDA-dependent congenital heart disease&#xD;
&#xD;
          -  Prior treatment with prophylactic indomethacin&#xD;
&#xD;
          -  Prior PDA treatment with any medications&#xD;
&#xD;
          -  Suspected or diagnosed acute necrotizing enterocolitis (NEC) or spontaneous intestinal&#xD;
             perforation&#xD;
&#xD;
          -  Abnormal liver enzymes (ALT &gt; 60 IU/L and AST &gt; 60 IU/L)&#xD;
&#xD;
          -  Platelets count &lt; 50,000 /Î¼l; and / or active intracranial, gastrointestinal, or other&#xD;
             bleeding&#xD;
&#xD;
          -  Major congenital anomalies such as neural tube defect, known or suspected chromosomal&#xD;
             abnormality, and gastrointestinal defect&#xD;
&#xD;
          -  Prior enrollment to other interventional clinical study where PDA is an outcome&#xD;
             variable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanket D Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

